Censavudine

Censavudine
Clinical data
Other names4'-ethynylstavudine, festinavir
Legal status
Legal status
  • Investigational
Identifiers
  • 1-[(2R,5R)-5-ethynyl-5-(hydroxymethyl)-2H-furan-2-yl]-5-methylpyrimidine-2,4-dione
CAS Number
PubChem CID
ChemSpider
UNII
KEGG
ChEMBL
NIAID ChemDB
CompTox Dashboard (EPA)
ECHA InfoCard100.225.812 Edit this at Wikidata
Chemical and physical data
FormulaC12H12N2O4
Molar mass248.238 g·mol−1
3D model (JSmol)
  • CC1=CN(C(=O)NC1=O)[C@H]2C=C[C@](O2)(CO)C#C
  • InChI=1S/C12H12N2O4/c1-3-12(7-15)5-4-9(18-12)14-6-8(2)10(16)13-11(14)17/h1,4-6,9,15H,7H2,2H3,(H,13,16,17)/t9-,12+/m1/s1
  • Key:OSYWBJSVKUFFSU-SKDRFNHKSA-N

Censavudine (INN;[1] development code BMS-986001) is an investigational new drug being developed by Bristol Myers-Squibb for the treatment of HIV infection.[2][3] It was originally developed at Yale University.[4] It is still in an investigational phase of development as of 2023.[5]

  1. ^ "International Nonproprietary Names for Pharmaceutical Substances (INN). Proposed International Nonproprietary Names: List 110" (PDF). World Health Organization. pp. 409–410.
  2. ^ Wu VH, Smith RA, Masoum S, Raugi DN, Ba S, Seydi M, et al. (August 2017). "MK-8591 (4'-Ethynyl-2-Fluoro-2'-Deoxyadenosine) Exhibits Potent Activity against HIV-2 Isolates and Drug-Resistant HIV-2 Mutants in Culture". Antimicrobial Agents and Chemotherapy. 61 (8). doi:10.1128/AAC.00744-17. PMC 5527656. PMID 28559249.
  3. ^ Gupta SK, McComsey GA, Lombaard J, Echevarría J, Orrell C, Avihingsanon A, et al. (January 2016). "Efficacy, safety, bone and metabolic effects of HIV nucleoside reverse transcriptase inhibitor BMS-986001 (AI467003): a phase 2b randomised, controlled, partly blinded trial". The Lancet. HIV. 3 (1): e13-22. doi:10.1016/S2352-3018(15)00231-3. hdl:1805/10552. PMID 26762988.
  4. ^ Alcorn K (21 December 2010). "Bristol-Myers Squibb buys festinavir, new NRTI active against MDR HIV". aidsmap.com. aidsmap. Retrieved 24 June 2011.
  5. ^ PubChem. "Censavudine". pubchem.ncbi.nlm.nih.gov. Retrieved 2023-10-24.